Search Results

Apollon Inc. , a medtech startup based in Seoul, will collaborate with the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology (MIT) with the aim of developing and conducting clinical trials of non-invasive CGMs using Raman spectroscopy for the next two years.

GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) (“GHG” or the “Company”) announces that the Company has now added additional exclusive global licenses for the countries of Israel, and the European Union (with extension to Morocco) from Apollon Formularies, plc.

Apollon Formularies plc and Aion Therapeutic Inc. are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells

GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) (“GHG” or the “Company”) is pleased to announce that it has completed its contractual obligations relating to the first stage of the binding Letter of Intent (“LOI”)

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027